Washington State University, Spokane, Washington.
Sr Care Pharm. 2022 Feb 1;37(2):55-61. doi: 10.4140/TCP.n.2022.55.
To provide a review of opicapone as a treatment for end-of-dose wearing off associated with long-term levodopa therapy in patients with Parkinson's disease (PD). PubMed, Web of Science, and Google Scholar were searched for relevant literature using the following terms: management, treatment, opicapone, BIA 9-1067, entacapone, and tolcapone. Current guidelines and the manufacturer's package inserts were also reviewed. Recent literature and published studies of opicapone in the management of wearing off. Long-term use of levodopa is associated with known complications of motor fluctuations and dyskinesia. The addition of a drug with fewer daily administrations may reduce the complexity of the current medication regimen, improve adherence, and reduce the risk of adverse events in older people with PD. The Food and Drug Administration (FDA) approved a new catechol--methyltransferase (COMT) inhibitor opicapone in combination with levodopa/carbidopa to treat wearing off in PD patients on April 24, 2020. Opicapone offers patients with PD a once-daily option with a favorable side effect profile, increased exposure to levodopa, and reduction in "off" time. It may be an appropriate second line option in patients who are intolerant or do not respond with entacapone.
提供了一种治疗帕金森病（PD）患者长期左旋多巴治疗相关的终末剂量失效的治疗方法，即opicapone。使用以下术语在 PubMed、Web of Science 和 Google Scholar 上搜索相关文献：管理、治疗、opicapone、BIA 9-1067、恩他卡朋和托卡朋。还审查了当前的指南和制造商的包装说明书。关于 opicapone 在治疗失效方面的最新文献和已发表的研究。长期使用左旋多巴与已知的运动波动和运动障碍并发症有关。使用每日服用次数较少的药物可能会降低当前药物治疗方案的复杂性，提高依从性，并降低老年 PD 患者发生不良事件的风险。美国食品和药物管理局（FDA）于 2020 年 4 月 24 日批准了一种新的儿茶酚-O-甲基转移酶（COMT）抑制剂 opicapone 与左旋多巴/卡比多巴联合用于治疗 PD 患者的终末剂量失效。opicapone 为 PD 患者提供了一种每日一次的选择，具有良好的副作用谱，增加了左旋多巴的暴露，并减少了“关闭”时间。对于恩他卡朋不耐受或无反应的患者，它可能是一种合适的二线选择。
Zotero 插件